التفاصيل البيبلوغرافية
| العنوان: |
Prognostic value of breast MRI characteristics before and during neoadjuvant endocrine therapy in patients with ER+/HER2- breast cancer |
| المؤلفون: |
Ragusi, Max Aa, Winter-Warnars, Gonneke Ao, Wesseling, Jelle, Linn, Sabine C., Beets-Tan, Regina G., van der Velden, Bas Hm, Elias, Sjoerd G., Gilhuijs, Kenneth Ga, Loo, Claudette E. |
| المساهمون: |
Beeldverwerking ISI, Cancer, MS MOD, Pathologie, Epi Infectieziekten, Epi Kanker Team A, JC onderzoeksprogramma Kanker |
| سنة النشر: |
2021 |
| مصطلحات موضوعية: |
Aged, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Aromatase Inhibitors/administration & dosage, Biomarkers, Tumor/analysis, Breast Neoplasms/diagnostic imaging, Contrast Media, Female, Humans, Magnetic Resonance Imaging/methods, Middle Aged, Neoadjuvant Therapy, Neoplasm Staging, Prognosis, Receptor, ErbB-2/analysis, Receptors, Estrogen/analysis, Retrospective Studies, Tamoxifen/administration & dosage, Radiology Nuclear Medicine and imaging, Observational Study, Journal Article |
| الوصف: |
OBJECTIVE: To investigate whether BIRADS MRI characteristics before or during neoadjuvant endocrine therapy (NET) are associated with the preoperative endocrine prognostic index (PEPI) in ER+/HER2- breast cancer patients. METHODS: This retrospective observational cohort study included 35 ER+/HER2- patients with 38 tumors (3 bilateral cases) treated with NET. The pre- and midtreatment (after 3 months) MRIs were evaluated by two breast radiologists for BIRADS imaging characteristics, shrinkage pattern, and radiologic response. PEPI was used as end point. PEPI is based on the post-treatment surgical specimen's pT- and pN-stage, Ki67, and ER-status. Tumors were assigned PEPI-1 (good prognosis) or PEPI-2/3 (poor prognosis). We investigated whether pre- and midtreatment BIRADS characteristics were associated with PEPI. RESULTS: Median patient age was 65 years (interquartile interval [IQI]: 53, 70). 17 tumors (44.7%) were associated with good prognosis (PEPI-1), and 21 tumors (55.3%) with poor prognosis (PEPI-2/3). A larger reduction in tumor size after 3 months of NET was significantly associated with PEPI; 10 mm (IQI: 5, 13.5) in PEPI-1 tumors vs 4.5 mm (IQI: 3, 7; p = .045) in PEPI-2/3 tumors. Other BIRADS characteristics, shrinkage pattern or radiologic response were not associated with PEPI. CONCLUSION: Only a larger reduction in tumor size on MRI after 3 months of NET was associated with PEPI-1 (good prognosis) in ER+/HER2- breast cancer patients. ADVANCES IN KNOWLEDGE: MRI characteristics previously reported to be associated with prognosis during neoadjuvant chemotherapy are not necessarily associated with prognosis during NET in ER+/HER2- breast cancer patients. |
| نوع الوثيقة: |
article in journal/newspaper |
| وصف الملف: |
application/pdf |
| اللغة: |
English |
| تدمد: |
1748-880X |
| العلاقة: |
https://dspace.library.uu.nl/handle/1874/443304Test |
| الإتاحة: |
https://dspace.library.uu.nl/handle/1874/443304Test |
| حقوق: |
info:eu-repo/semantics/ClosedAccess |
| رقم الانضمام: |
edsbas.DB571F0C |
| قاعدة البيانات: |
BASE |
